happy-news-for-novartis-geneva-production-site-employees-novartis-will-invest-usd160-million-until-2020

Novartis spends $160 mn to jumpstart factory

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Novartis is going to invest $160 million (CHF150 million) until 2020 to bolster its production site near Geneva. The firm was contemplating a shut down... Read more

novozymes-reports-five-percent-sales-growth-in-q1-2013

Novozymes reports 5% sales growth in Q1 2013

  • Europe
  • |
  • Company Results
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Novozymes, bioinnovation and industrial enzymes, has reported five percent growth in first quarter of 2013. "Overall, the first quarter was as expected.... Read more

the-drugs-on-european-medicines-agency-s-list-will-display-an-inverted-back-triangle-in-their-package-leaflet

EMA publishes list of drugs to be monitored

  • Europe
  • |
  • Regulatory
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: European Medicines Agency has published the initial list of medicines that are subject to additional monitoring. This represents an important deliverable... Read more

while-novartis-incoming-chairman-dr-joerg-reinhardt-will-get-usd4

Novartis to pay $4mn to incoming chairman

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Novartis revealed that it would pay Dr Joerg Reinhardt, the firm's incoming chairman of the board (effective August 1, 2013), a total annual compensation... Read more

good-news-for-ischemia-patients-phylogica-gets-european-patent-for-its-peptide-inhibitors-that-target-the-ap-1-pathway

EU patent for Phylomer ischemia peptides

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Phylogica has been granted a new European patent (no. 1793841) entitled: ‘Peptide inhibitors of c-Jun dimerization and uses thereof'. This international... Read more

oncotest-debiopharm-identify-biomarker-candidates

Oncotest, Debiopharm identify biomarker candidates

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Germany-based Oncotest and Debiopharm, a Swiss-based global biopharmaceutical group, have completed first biomarker projects at Oncotest. The pharmacological... Read more

lonza-manufactures-bionomics-anti-cancer-stem-cell-candidate-bnc101

Lonza produces Bionomics’ stem cell cancer drug

  • Australia
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Bionomics has initiated manufacturing activities for BNC101, its lead anti-cancer stem cell candidate following completion of key preclinical studies.... Read more

good-news-for-cancer-patients-astrazeneca-and-bind-therapeutics-to-develop-and-commercialize-targeted-and-programmable-cancer-nanomedicine-accurin

AstraZeneca, Bind develop cancer nanomedicine

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: AstraZeneca and Bind Therapeutics entered into a strategic collaboration to develop and commercialize Accurin, a targeted and programmable cancer nanomedicine... Read more

orchid-allecra-to-develop-antibiotics-to-combat-multi-drug-resistant-bacterial-infections

India, EU firms fight 'epidemic of drug-resistance'

  • India
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: India-based Orchid Pharma entered into a strategic partnership with Europe-based Allecra Therapeutics to develop novel antibiotics to combat multi-drug... Read more

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X